Related Experiment Video

Updated: May 23, 2026

Depletion and Reconstitution of Macrophages in Mice
08:50

Depletion and Reconstitution of Macrophages in Mice

Published on: August 1, 2012

Albendazole and colchicine modulate LPS-induced secretion of inflammatory mediators by liver macrophages

A V Viktorov1, V A Yurkiv

  • 1Laboratory for Molecular Mechanisms of Infection, Research Institute of Epidemiology, Moscow, Russia. viktorov_av@yahoo.com

Bulletin of Experimental Biology and Medicine
|April 10, 2012
PubMed

Insights

Colchicine and albendazole reduced tumor necrosis factor-alpha (TNF-α) and nitric oxide (NO) release from rat Kupffer cells. These drugs also increased prostaglandin E2 secretion, impacting inflammatory responses.

Area of Science:

  • Immunology
  • Pharmacology
  • Cell Biology

Background:

  • Kupffer cells are key immune cells in the liver.
  • Lipopolysaccharide (LPS) is a potent activator of Kupffer cells, triggering inflammatory mediator release.
  • Tumor necrosis factor-alpha (TNF-α), nitric oxide (NO), and prostaglandins are critical inflammatory mediators.

Purpose of the Study:

  • To investigate the effects of colchicine and albendazole on LPS-induced inflammatory mediator secretion in rat Kupffer cells.
  • To determine the impact of these drugs on the release of TNF-α, NO, prostaglandin E2 (PGD2), and prostaglandin D2 (PGD2).

Main Methods:

  • Primary culture of rat Kupffer cells was established.
  • Cells were stimulated with LPS in the presence or absence of colchicine and albendazole.
  • Secretion levels of TNF-α, NO, PGD2, and PGD2 were measured.

Main Results:

  • Colchicine and albendazole significantly inhibited LPS-induced secretion of TNF-α and NO.
  • Both agents potentiated the LPS-stimulated secretion of prostaglandin E2.
  • The secretion of prostaglandin D2 was not significantly altered by colchicine or albendazole treatment.

Conclusions:

  • Colchicine and albendazole modulate inflammatory mediator release from Kupffer cells.
  • These drugs exhibit differential effects on pro-inflammatory and anti-inflammatory prostaglandin pathways.
  • Findings suggest potential therapeutic roles for colchicine and albendazole in managing inflammatory conditions involving Kupffer cells.

More Related Videos

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat09:04

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms: